Acro Biomedical Co., Ltd. in brief
Acro Biomedical Co., Ltd. is a listed company in the Biotechnology industry, based in Fishers, Indiana, USA. It was founded in 2014. Its last known market value was $240 M (December 2022); there is no current figure.
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Acro Biomedical Co., Ltd.
Since January 30, 2017, following a change of control, our business has been the development and marketing nutritional products that promote wellness and a healthy lifestyle. Our revenue to date has resulted from the purchase of products from three suppliers in the Republic of China (Taiwan), one of which accounted for all of our purchases in the year ended December 31, 2022. We have not generated any revenue in the second and third quarters of 2022 and subsequent to December 31, 2022 through the date of this annual report, and we did not purchase any inventory since the second quarter of 2022.
From the company's annual report filed with the US SEC: read the report
Acro Biomedical Co., Ltd. timeline
- 2014
- 🏁· approximateFounded
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- ✎Renamed Acro Biomedical Co., Ltd.Formerly Killer Waves Hawaii, Inc.
- 2021
- 💰Record revenue of $1 millionFY2021, the highest of the 4 years on record.
Events of Acro Biomedical Co., Ltd. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,333 (Jan 2020) · #3,487 (Jan 2021) · #3,602 (Jan 2022) · #3,486 (Dec 2022)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- —
- Liabilities / assets
- 4000.0%
- Revenue growth
- -45.0%
- R&D / revenue
- 1527.3%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-0M | $-0M | — |
| Dec 2024 | — | — | $-0M | $-0M | — |
| Dec 2023 | — | — | $-9M | $-9M | — |
| Dec 2022 | $1M | -45.0% | $-16M | $-16M | -2404.5% |
| Dec 2021 | $1M | +73.9% | $-8M | $-8M | -641.7% |
| Dec 2020 | $1M | +263.2% | $-0M | $-0M | -17.4% |
| Dec 2019 | $0M | -97.6% | $-0M | $-0M | -194.7% |
| Sep 2018 | $8M | — | $1M | $0M | 5.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-0M | — | — | $0.00 | — |
| Dec 2024 | $-0M | — | — | $0.00 | — |
| Dec 2023 | $-0M | — | — | $-0.15 | — |
| Dec 2022 | $-0M | — | — | $-0.26 | — |
| Dec 2021 | $0M | — | — | — | — |
| Dec 2020 | $-0M | — | — | $0.00 | — |
| Dec 2019 | $-0M | — | — | $-0.01 | — |
| Sep 2018 | $-0M | — | — | $0.01 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Sep 2, 20268-KCurrent reportDirectors or officers changed
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- May 5, 202610-QQuarterly report · period to Mar 2026
- Feb 11, 202610-KAnnual report · period to Dec 2025
- Jan 8, 20268-KCurrent reportAuditor change
- Nov 10, 202510-QQuarterly report · period to Sep 2025
- Aug 14, 20258-KCurrent reportDirectors or officers changed
- Aug 5, 202510-QQuarterly report · period to Jun 2025
- Jul 24, 202510-QQuarterly report · period to Mar 2025
- Jul 24, 202510-KAnnual report · period to Dec 2024
- Jul 23, 202510-QQuarterly report · period to Sep 2024
- Jul 23, 202510-QQuarterly report · period to Jun 2024
Official filings of Acro Biomedical Co., Ltd. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-0 M
- Net income
- $-0 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $0 M
- Total liabilities
- $0 M
- Total equity
- $-0 M
As of December-2025
Markets and events: Acro Biomedical Co., Ltd.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 2-for-1 split
Acro Biomedical Co., Ltd. scorecard#
Passes 2 of the 7 checks that could be worked out. Fiscal year 2025.
Valuationnot known
Growth1 of 2
Profitability0 of 2
Financial health0 of 2
Shareholder returns1 of 1
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Acro Biomedical Co., Ltd.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Sep 30, 2019 | FY 2018to Sep 30, 2018 | FY 2017to Sep 30, 2017 | FY 2016to Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0 | 0 | 0 | 659 | 1,198 | 688 | 1,354 | 8,015 | 510 | — | |
| Cost of revenue | — | — | 0 | 518 | 938 | 529 | 1,219 | 7,181 | 459 | — | |
| Gross profit | — | — | 0 | 141 | 260 | 159 | 135 | 833 | 51 | — | |
| Research and development | — | 0 | 4,795 | 10,080 | 5,285 | — | — | — | — | — | |
| Selling, general and administrative | 154 | 38 | 3,518 | 5,930 | 2,668 | 290 | 577 | 318 | 53r | 1.1 | |
| Operating expenses | 154 | 38 | 8,804 | 16,010 | 7,953 | 290 | 577 | 318 | 53 | 43 | |
| Operating income | −154 | −38 | −8,804 | −15,870 | −7,694 | −130 | −442 | 516 | −2.2 | 43 | |
| Interest expense and finance costs | — | — | 3.2 | 1.7r | 0.9 | 1.1 | — | — | — | — | |
| Other non-operating income (expense) | 53 | −4.3 | — | — | — | −5.1 | −2.3 | −3.7 | — | — | |
| Income before tax | −101 | −42 | −8,808 | −15,871 | — | −136 | −444 | 512 | −2.2 | −43 | |
| Income tax | 0 | 0 | 0 | 0 | 0 | −18 | −73 | 92 | 0 | 0 | |
| Net income including minority interests | −101 | −42 | −8,808r | 15,871 | — | — | — | — | — | — | |
| Net income attributable to shareholders | −101 | −42 | −8,808 | −15,871 | −7,698 | −117 | −371 | 420 | −2.2 | −43 | |
| Earnings per share, basic | — | — | — | — | -0.14 | 0.00 | -0.01 | 0.01 | 0.00 | 0.00 | |
| Earnings per share, diluted | 0.00 | 0.00 | -0.15 | -0.26 | — | 0.00 | -0.01 | 0.01 | 0.00 | 0.00 | |
| Shares, weighted average (diluted) | 60 | 60 | 60 | 60 | 54 | 48 | 48 | 48 | 47 | 47r | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 4.1 | 0.5 | 0.4 | 5.9 | 95 | 18 | 1.5 | 1.1 | 37 | 2.5 | |
| Receivables | — | — | 0 | 639 | 598 | — | — | — | — | — | |
| Inventory | — | — | — | — | 0 | 938 | 1,060 | 1,147 | 481 | — | |
| Current assets | 14 | 5.1 | 1.6 | 658 | 706 | 973 | 1,069 | 1,478 | 548 | 2.5 | |
| Right-of-use (leased) assets | 0 | 27 | 52 | 26 | 50 | 25 | — | — | — | — | |
| Total assets | 14 | 32 | 58 | 687 | 761 | 998 | 1,069 | 1,483 | 548 | 2.5 | |
| Accounts payable | 56 | 154 | 154 | 77 | 26 | 25 | 18 | 7.3 | 0.6 | 7.3 | |
| Current liabilities | 401 | 327 | 289 | 201 | 92 | 312 | 196 | 241 | 37 | 17 | |
| Lease liabilities (non-current) | — | 0 | 27 | 0 | 26 | 0 | — | — | — | — | |
| Total liabilities | — | 327 | 315 | 201 | 117 | 312 | 196 | 241 | 37 | 17 | |
| Retained earnings | −32,759 | −32,658 | −32,615 | −23,808 | −7,936 | −239 | −45 | 325 | −94 | −92 | |
| Shareholders' equity | −387 | −295 | −257 | 486 | 644 | 686 | 874 | 1,242 | 511 | −15 | |
| Total liabilities and equity | 14 | 32 | 58 | 687 | 761 | 998 | 1,069 | 1,483 | 548 | 2.5 | |
| Shares outstanding | 60 | 60 | 60 | 60 | 60r | 48 | 48 | 48 | 48 | 47r | |
| Cash-flow statement | |||||||||||
| Share-based compensation | — | 0 | 8,061 | 15,712 | 7,651 | 0 | 300 | 7.4 | — | — | |
| Cash from operating activities | −196 | −37 | −15 | −147 | 299 | −199 | 80 | −140 | −463 | −35 | |
| Shares issued | — | — | — | — | — | — | — | — | 500 | — | |
| Cash from financing activities | 200 | 37 | 10.0 | 58 | −222 | 217 | −79 | 105 | 498 | 10 | |
| Change in cash | — | — | — | — | — | 17 | 0.3 | −36 | 34 | −25 | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Jun 30, 2026
Events at Acro Biomedical Co., Ltd.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Auditor changed 3 · Directors and officers 3 · Bylaws or fiscal year changed 1 · Shareholder vote 1
As of Sep 2, 2026
How Acro Biomedical Co., Ltd. compares in Biotechnology
- Revenue growth-45.0% · higher than 21% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Acro Biomedical Co., Ltd.🇺🇸 | $240 M | — | — | -45.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
How current the figures are
- Market cap:
- Dec 25, 2022 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Acro Biomedical Co., Ltd.? Verify and update this profile — free
Show Acro Biomedical Co., Ltd.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.